# TIGIT blockade

Source: https://onco.cc/technologies/tigit-blockade/  
OnCo record `tigit-blockade` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Antibodies against TIGIT, a brake on T cells and natural killer cells, tested alongside PD-L1 drugs; the biggest lung cancer trials so far have failed.

## Summary

TIGIT is an inhibitory receptor on T and natural killer cells that competes with the activating receptor CD226 for the ligand CD155. Tiragolumab (Roche) reached phase 3 with atezolizumab after promising phase 2 results in lung cancer, but the SKYSCRAPER programme did not improve survival, and several rivals paused development. Fc-active and Fc-silent antibodies, and combinations in other tumours, are still being tested.

## Fields

- Kind: Technology
- Status: phase-3
- Last checked: 2026-09-04
- Principle: Monoclonal antibodies bind TIGIT to stop it engaging CD155, freeing CD226 co-stimulation; Fc-active versions may also deplete regulatory T cells.
- Strengths: Complements PD-1/PD-L1 blockade mechanistically; Well tolerated in trials
- Limitations: Phase 3 lung cancer trials negative; Benefit, if any, confined to undefined subgroups; Fc-format questions unresolved

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/TIGIT
- Wikipedia: https://en.wikipedia.org/wiki/TIGIT

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- targets: [TIGIT](https://onco.cc/targets/tigit/)
- drugs: [Tiragolumab](https://onco.cc/drugs/tiragolumab/)

---
JSON: https://onco.cc/api/v1/entities/tigit-blockade.json